Related Experiment Video
Updated: Aug 8, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
[Methotrexate-induced interstitial pneumonitis in a child with acute lymphoblastic leukemia]
Chiho Tatsumoto1, Kiyoshi Kawakami, Jun Nagayama
1Department of Pediatrics, Kagoshima City Hospital.
Insights
Methotrexate (MTX) can cause interstitial pneumonitis in children with acute lymphoblastic leukemia. This rare complication requires physician awareness during maintenance therapy.
Area of Science:
- Pediatric Oncology
- Pulmonology
- Pharmacology
Background:
- Acute lymphoblastic leukemia (ALL) is a common childhood cancer.
- Methotrexate (MTX) is a key chemotherapeutic agent used in ALL treatment.
- Long-term, low-dose MTX is often employed for maintenance therapy.
Observation:
- A 5-year-old boy with ALL developed fever, cough, dyspnea, and hypoxemia during MTX maintenance therapy.
- Clinical, radiological, and laboratory findings supported a diagnosis of MTX-induced interstitial pneumonitis.
- The patient's condition improved after discontinuing MTX.
Findings:
- MTX-induced interstitial pneumonitis is a recognized adverse effect, though rarely reported in pediatric leukemia.
- This case highlights a potential severe pulmonary complication of low-dose MTX in children with ALL.
- The prevalence in adult rheumatoid arthritis patients is 0.3-7.5%, but data in pediatric leukemia is scarce.
Implications:
- Physicians must consider MTX pneumonitis in children with ALL presenting with respiratory symptoms during maintenance therapy.
- Early recognition and MTX cessation are crucial for patient recovery.
- Further research is needed to understand the incidence and risk factors of MTX pneumonitis in pediatric leukemia.
Abstract:
We report a case of 5-year-old boy with acute lymphoblastic leukemia who developed interstitial pneumonitis induced by methotrexate (MTX). The patient was hospitalized with fever, cough, dyspnea and hypoxemia during maintenance treatment with low dose MTX and 6-mercaptopurine. A diagnosis of MTX pneumonitis was made based on the clinical findings, viral and serologic studies, negative microbiology and the radiological features. The patient recovered after cessation of the MTX treatment. Interstitial pneumonitis caused by MTX is well-recognized and the prevalence has been estimated to be 0.3-7.5% among patients with adult rheumatoid arthritis. However, there are few reports in the literature regarding this adverse effect in patients with leukemia. Furthermore, very few cases of childhood leukemia have been reported regarding MTX induced interstitial pneumonitis. Physicians should be aware of this rare complication during maintenance treatment with weekly low dose MTX for acute lymphoblastic leukemia in children.
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
